Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 547

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Global liver disease burdens and research trends: Analysis from a Chinese perspective

Xiao, Jia, Wang, Fei, Wong, Nai-Kei, He, Jinhan, Zhang, Rui, Sun, Ruijuan, Xu, Yanying, Liu, Yingxia, Li, Wei, Koike, Kazuo, He, Weiling, You, Hong, Miao, Yinglei, Liu, Xiaowei, Meng, Mingming, Gao, Bin, Wang, Hua, Li, Cui·2019·Journal of Hepatology

Abstract

Liver diseases affect millions of people worldwide. In most developed countries, the incidence of viral hepatitis is waning as a result of modern advances in disease prevention, diagnosis, and therapies. Expanded programmes for systematic immunisation against hepatitis B virus have also significantly brought down the number of new cases in many countries, including China. In contrast, with the improvement in living standards, the prevalence of metabolic liver diseases including non-alcoholic fatty liver disease and alcohol-related liver disease is set to rise, ultimately leading to more cases of end-stage liver diseases (liver failure, cirrhosis, and liver cancer). Over the past 30 years, visionary governments of major nations have provided strong incentives for basic/clinical research, vaccination programmes, and drug discovery and development in the field of hepatology. To get rid of her unflattering title as the "leader in liver diseases", China has also made a serious effort to initiate nationwide preventive measures for liver diseases, global partnerships, and mentoring programmes for young hepatologists. Instrumental to such progress is the continuous support of the National Natural Science Foundation of China (NSFC), which has helped hepatology to thrive in virtually all research directions within the country. In this article, we seek to provide stimulating glimpses into the evolving liver disease epidemiology, institutional research profiles, funding landscape, and drug development trends in China, with an attempt to compare her status and achievements with those of the United States, European countries, and Japan.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2019.03.004

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 8

  1. Ohishi, 2009, Current treatment for chronic hepatitis B in Japan, Clin J Gastroenterol, 2, 325, 10.1007/s12328-009-0100-1 · doi:10.1007/s12328-009-0100-1
  2. Rao, 2014, Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection, J Gastroenterol Hepatol, 29, 545, 10.1111/jgh.12398 · doi:10.1111/jgh.12398
  3. Goyal, 2016, Cost-effectiveness of peg-interferon, interferon and oral nucleoside analogues in the treatment of chronic hepatitis B and D infections in China, Clin Drug Invest, 36, 637, 10.1007/s40261-016-0409-8 · doi:10.1007/s40261-016-0409-8
  4. 2016, Guideline of prevention and treatment for hepatitis C (2015 Update), J Pract Hepatol, 19, S9
  5. Lu, 2018, Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China, PLoS ONE, 13
  6. Chang, 2018, Analysis and suggestions on the situation of hepatitis C treatment and related medical insurance compensation mechanism in China, China Pharm, 29, 151
  7. Ellis, 2018, Biotech booms in China, Nature, 553, S19, 10.1038/d41586-018-00542-3 · doi:10.1038/d41586-018-00542-3
  8. Grueber, 2014, 2014 global R&D funding forecast, R&D Magazine, 16, 1

Cited by

See all 547

Metadata

Authors
Xiao, J., Wang, F., Wong, N.-K., He, J., Zhang, R., Sun, R., Xu, Y., Liu, Y., Li, W., Koike, K., He, W., You, H., Miao, Y., Liu, X., Meng, M., Gao, B., Wang, H., & Li, C.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2019-07
Volume
71
Issue
1
Pages
212-221
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2922188864
Cited by
547
References
36
FWCI
38.92
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global liver disease burdens and research trends: Analysis from a Chinese perspective. https://app.cochat.ai/papers/10.1016/j.jhep.2019.03.004
The paper
Xiao, J., Wang, F., Wong, N.-K., He, J., Zhang, R., Sun, R., Xu, Y., Liu, Y., Li, W., Koike, K., He, W., You, H., Miao, Y., Liu, X., Meng, M., Gao, B., Wang, H., & Li, C. (2019). Global liver disease burdens and research trends: Analysis from a Chinese perspective. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2019.03.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.